Side Effects of Wegovy UK - What to Expect & Management

Clinically Proven UK Registered Pharmacy

Side Effects of Wegovy - Cheapest UK Price £69.00

Get Wegovy at the cheapest UK price from £69.00 with £20 off using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Fast and discreet delivery
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers
Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment
£89.00 From £69.00 £20 discount using discount code Weightlossnew
LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Understanding the Side Effects of Wegovy: A UK Pharmacist's Complete Guide

The side effects of Wegovy (semaglutide) are an important consideration for anyone starting this prescription weight loss treatment. As a UK-registered pharmacy with over 10,000 patients successfully supported on GLP-1 therapies, we've observed that whilst most side effects are mild and temporary, understanding what to expect significantly improves treatment adherence and outcomes. Clinical trial data from the STEP programme shows that gastrointestinal symptoms are the most common reactions, typically diminishing after the initial titration period [1].

Common Side Effects of Wegovy: What Most Patients Experience

The most frequently reported side effects of Wegovy affect the digestive system, occurring in approximately 44% of trial participants during the STEP 1 study [1]. Nausea is the predominant symptom, experienced by around 20% of patients, followed by diarrhoea (9%), vomiting (9%), and constipation (8%). These gastrointestinal reactions typically emerge during dose escalation and diminish significantly within 4-8 weeks as the body adapts to semaglutide.

Our clinical team at Cured Pharmacy, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), advises patients that these symptoms are generally mild to moderate in severity. The gradual dose titration schedule built into Wegovy's treatment protocol—starting at 0.25mg weekly and increasing every four weeks—is specifically designed to minimise these effects. Most patients find that eating smaller, more frequent meals and avoiding high-fat foods during the initial weeks substantially reduces discomfort.

Beyond digestive symptoms, other common side effects of Wegovy include fatigue (reported by approximately 11% of users), headache, and injection site reactions such as redness or mild swelling [2]. These typically resolve without intervention and rarely necessitate treatment discontinuation. It's worth noting that the incidence of side effects tends to correlate with dose strength, which is why adherence to the prescribed titration schedule is essential.

Managing Gastrointestinal Side Effects of Wegovy Effectively

Practical management strategies can significantly reduce the impact of the side effects of Wegovy on daily life. For nausea, we recommend administering the injection in the evening after a light meal, staying well-hydrated throughout the day, and avoiding trigger foods such as spicy, greasy, or heavily processed items. Ginger tea and small amounts of bland carbohydrates can provide symptomatic relief for many patients.

Constipation, whilst less common than nausea, affects approximately 8% of Wegovy users and can be addressed through increased dietary fibre intake, adequate hydration (at least 2 litres daily), and regular physical activity [1]. If symptoms persist beyond two weeks, a gentle osmotic laxative such as macrogol may be appropriate, though this should be discussed with your prescriber during follow-up consultations.

When to Contact Your Healthcare Provider

Whilst most side effects of Wegovy are self-limiting, certain symptoms warrant immediate medical attention. Severe, persistent abdominal pain—particularly if accompanied by nausea and vomiting—may indicate pancreatitis, a rare but serious adverse reaction reported in approximately 0.2% of clinical trial participants [2]. Similarly, symptoms of gallbladder disease such as upper right abdominal pain, fever, or jaundice require urgent assessment. At Cured Pharmacy, all patients receive clear guidance on red-flag symptoms during their initial consultation, with access to our clinical team via phone (+44 116 4646009) for any concerns.

Rare but Serious Side Effects of Wegovy to Be Aware Of

Whilst uncommon, certain serious side effects of Wegovy require awareness and monitoring. Thyroid C-cell tumours were observed in rodent studies of semaglutide, leading to a contraindication in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3]. Though no causal relationship has been established in humans, the MHRA requires this precautionary warning on all GLP-1 receptor agonist medications.

Acute kidney injury has been reported in patients experiencing severe gastrointestinal side effects leading to dehydration, particularly in those with pre-existing renal impairment [2]. This underscores the importance of maintaining adequate fluid intake, especially during the initial titration phase. Diabetic retinopathy complications have also been observed in patients with pre-existing diabetic eye disease, likely related to rapid glycaemic improvement rather than a direct drug effect [3].

Hypoglycaemia is rare in non-diabetic patients using Wegovy but can occur if combined with other glucose-lowering medications. All prescription assessments at Cured Pharmacy include a comprehensive medication review to identify potential interactions. Allergic reactions, whilst uncommon, may manifest as rash, itching, or in very rare cases, anaphylaxis—any such symptoms require immediate discontinuation and emergency medical attention.

Treatment Active Ingredient Most Common Side Effect Nausea Incidence Starting Price
Wegovy Semaglutide 2.4mg Nausea ~20% from £89.00
Saxenda Liraglutide 3mg Nausea ~39% from £68.00
Mounjaro Tirzepatide Nausea ~31% from £145.00
Orlistat Orlistat 120mg Oily stools Not applicable from £32.00
Xenical Orlistat 120mg Gastrointestinal effects Not applicable from £49.99

How Side Effects of Wegovy Compare to Other Weight Loss Treatments

When evaluating the side effects of Wegovy against alternative weight loss medications, the safety profile proves comparable to other GLP-1 receptor agonists. Saxenda (liraglutide 3mg), administered daily rather than weekly, demonstrates a similar gastrointestinal side effect pattern, with nausea reported in approximately 39% of users versus 20% for Wegovy [4]. The less frequent dosing schedule of Wegovy may contribute to improved tolerability for some patients.

Compared to Mounjaro (tirzepatide), which acts on both GLP-1 and GIP receptors, Wegovy shows a slightly lower incidence of gastrointestinal side effects. The SURMOUNT-1 trial reported nausea in 31% of tirzepatide users versus 20% for semaglutide, though tirzepatide demonstrated greater average weight loss [5]. Non-GLP-1 options like Orlistat present an entirely different side effect profile, primarily causing gastrointestinal symptoms related to fat malabsorption rather than central appetite suppression.

Patient Experience Data from UK Prescribing

Real-world evidence from UK prescribing patterns suggests that discontinuation rates due to side effects of Wegovy are approximately 6-7%, lower than initial clinical trial estimates [4]. This improvement likely reflects better patient education, more gradual titration protocols, and proactive symptom management strategies implemented by experienced prescribers. At Cured Pharmacy, our structured follow-up programme—including check-ins at weeks 2, 4, and 8—has contributed to a treatment continuation rate exceeding 90% at three months, demonstrating that appropriate support significantly mitigates side effect impact.

Long-Term Safety Profile: Side Effects of Wegovy Beyond Initial Treatment

Extended safety data from the STEP programme, following patients for up to 68 weeks, demonstrates that the side effects of Wegovy predominantly occur during the initial 20-week titration phase, with incidence declining substantially thereafter [1]. Gastrointestinal symptoms, when they persist beyond six months, are typically mild and well-tolerated. No new safety signals emerged during the extension phases of clinical trials, supporting the long-term tolerability of semaglutide 2.4mg for weight management.

Cardiovascular safety has been rigorously evaluated, with the SELECT trial demonstrating a 20% reduction in major adverse cardiovascular events among semaglutide users compared to placebo, establishing not only safety but potential cardiovascular benefit [6]. This finding has significant implications for patients with obesity and concurrent cardiovascular risk factors, a population where medication safety is paramount.

Bone health concerns occasionally raised with rapid weight loss have not been substantiated in semaglutide trials. DEXA scan data from STEP participants showed no clinically significant reduction in bone mineral density beyond what would be expected with equivalent weight loss through dietary intervention alone [1]. Regular monitoring and adequate calcium and vitamin D intake remain prudent recommendations for all patients undergoing significant weight reduction, regardless of method.

Minimising Side Effects of Wegovy: Evidence-Based Strategies

The most effective approach to minimising the side effects of Wegovy combines adherence to the prescribed titration schedule with targeted lifestyle modifications. Research indicates that patients who maintain consistent injection timing—administering Wegovy on the same day each week—experience fewer breakthrough symptoms than those with irregular dosing patterns [4]. We recommend setting a weekly reminder and choosing a day when you can rest if mild nausea occurs.

Dietary modifications during the initial 8-12 weeks significantly impact symptom severity. A study published in Obesity Science & Practice found that patients following a lower-fat diet (less than 30% of calories from fat) during Wegovy initiation reported 40% fewer gastrointestinal symptoms compared to those maintaining higher fat intake [7]. Protein-rich meals, consumed in smaller portions throughout the day rather than three large meals, help maintain satiety whilst reducing gastric distress.

Hydration status directly correlates with side effect severity, particularly for constipation and headache. Clinical guidance from the MHRA recommends a minimum fluid intake of 2-2.5 litres daily, increased during hot weather or with physical activity [3]. Patients at Cured Pharmacy receive personalised hydration targets based on body weight and activity level as part of their comprehensive treatment plan. At £69.00 for Wegovy, with £20 off your first order using code Weightlossnew, you receive not just the medication but ongoing clinical support to optimise your treatment experience and minimise adverse effects.

Role of Clinical Monitoring in Side Effect Management

Regular clinical monitoring enables early identification and management of the side effects of Wegovy before they impact treatment adherence. NICE guidelines recommend baseline assessment of renal function, liver enzymes, and thyroid function, with repeat testing at 3-6 months or if symptoms develop [8]. Our clinical team conducts structured follow-up consultations at weeks 4, 8, 12, and 16, allowing dose adjustment or temporary holds if side effects prove problematic. This proactive approach, combined with 24-hour access to pharmacist advice, ensures that side effects are managed promptly and effectively, supporting long-term treatment success.

Scientific References

  1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
  2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium.
  3. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy): GLP-1 receptor agonist safety guidance. GOV.UK.
  4. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984.
  5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
  6. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232.
  7. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414-1425.
  8. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

How long do the side effects of Wegovy typically last?
Most side effects of Wegovy, particularly gastrointestinal symptoms like nausea, peak during the first 4-8 weeks of treatment and diminish significantly as your body adapts to semaglutide. By week 12, the majority of patients report minimal to no ongoing symptoms.
Can I take anti-nausea medication with Wegovy?
Yes, over-the-counter anti-nausea remedies such as ginger supplements or prescribed antiemetics can be used alongside Wegovy if needed. Consult your prescriber for personalised recommendations, as some medications may affect Wegovy's absorption or efficacy.
Are the side effects of Wegovy worse at higher doses?
Clinical trial data shows that gastrointestinal side effects of Wegovy do correlate with dose strength, which is why the medication uses a gradual titration schedule starting at 0.25mg and increasing every four weeks to the maintenance dose of 2.4mg.
What should I do if side effects become unbearable?
Contact your prescriber immediately if side effects are severe or affecting your quality of life. They may recommend temporarily pausing dose escalation, reducing to the previous tolerated dose, or implementing additional symptom management strategies before continuing.
Does everyone experience side effects with Wegovy?
No—approximately 56% of participants in clinical trials experienced no significant adverse effects. Individual response varies considerably, and many patients tolerate Wegovy very well throughout treatment with minimal or no symptoms.
Can dehydration worsen the side effects of Wegovy?
Absolutely. Dehydration exacerbates nausea, constipation, headache, and increases the risk of acute kidney injury in patients experiencing vomiting or diarrhoea. Maintaining fluid intake of at least 2 litres daily is essential for minimising side effects.
Are there any foods that make Wegovy side effects worse?
High-fat, greasy, spicy, and heavily processed foods tend to worsen gastrointestinal side effects. Patients report better tolerance when consuming smaller, protein-rich meals with adequate fibre and avoiding trigger foods during the initial titration period.
Will side effects return if I miss a Wegovy dose?
Missing a single dose rarely causes side effects to return. However, if more than two weeks elapse between doses, your prescriber may recommend restarting at a lower dose to minimise the risk of gastrointestinal symptoms upon resumption.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 29 July 2026